Home

Hepion Pharmaceuticals, Inc. - Common Stock (HEPA)

0.4402
+0.0002 (0.05%)
NASDAQ · Last Trade: Apr 8th, 9:57 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Hepion Pharmaceuticals (NASDAQ: HEPA) Reports Promising Phase 2 Trial Results for NASH Treatment
Renocofilstat's Positive Outcomes Reinforce Antifibrotic Action Hepion Pharmaceuticals, a clinical stage biopharmaceutical company focusing on AI-assisted therapeutic drug development, recently
Via Spotlight Growth · May 22, 2023